Identification of sites responsible for the potentiating effect of niflumic acid on ClC-Ka kidney chloride channels

British Journal of Pharmacology

Volumn 160, Issue 7, 2010, Pages 1652-1661

  Zifarelli, G ^a   Liantonio, A ^a,b   Gradogna, A ^a   Picollo, A ^a   Gramegna, G ^a,b   De Bellis, M ^a,b   Murgia, A R ^a   Babini, E ^a   Conte Camerino, D ^b   Pusch, M ^a  

^a CNR   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

NFA; niflumic acid

Indexed keywords

CHLORIDE CHANNEL; CLC KA PROTEIN; NIFLUMIC ACID; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG BINDING SITE; DRUG POTENTIATION; EXTRACELLULAR SPACE; FEMALE; GENE MUTATION; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SITE DIRECTED MUTAGENESIS; VOLTAGE CLAMP; WILD TYPE; XENOPUS;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; CHLORIDE CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ION CHANNEL GATING; KIDNEY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NIFLUMIC ACID; OOCYTES; PATCH-CLAMP TECHNIQUES; SEQUENCE ALIGNMENT; TRANSFECTION; XENOPUS;

EID: 77954332108     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00822.x     Document Type: Article

References (47)

1. Abitbol I, Peretz A, Lerche C, Busch AE, Attali B (1999). Stilbenes and fenamates rescue the loss of I(KS) channel function induced by an LQT5 mutation and other IsK mutants. Embo J 18:4137 4448.
2. Accardi A, Pusch M (2003). Conformational changes in the pore of CLC-0. J Gen Physiol 122:277 293.
3. Adachi S, Uchida S, Ito H, Hata M, Hiroe M, Marumo F et al. (1994). Two isoforms of a chloride channel predominantly expressed in thick ascending limb of Henle's loop and collecting ducts of rat kidney. J Biol Chem 269:17677 17683.
4. Akizuki N, Uchida S, Sasaki S, Marumo F (2001). Impaired solute accumulation in inner medulla of Clcnk1-/- mice kidney. Am J Physiol Renal Physiol 280:F79 F87.
5. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 209.
6. Birkenhäger R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I et al. (2001). Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310 314.
7. Busch AE, Herzer T, Wagner CA, Schmidt F, Raber G, Waldegger S et al. (1994). Positive regulation by chloride channel blockers of IsK channels expressed in Xenopus oocytes. Mol Pharmacol 46:750 753.
8. Cheng L, Sanguinetti MC (2009). Niflumic acid alters gating of HCN2 pacemaker channels by interaction with the outer region of S4 voltage sensing domains. Mol Pharmacol 75:1210 1121.
9. Coyne L, Su J, Patten D, Halliwell RF (2007). Characterization of the interaction between fenamates and hippocampal neuron GABA(A) receptors. Neurochem Int 51:440 446.
10. Dutzler R, Campbell EB, Cadene M, Chait BT, MacKinnon R (2002). X-ray structure of a ClC chloride channel at 3.0 Å reveals the molecular basis of anion selectivity. Nature 415:287 294.
11. Dutzler R, Campbell EB, MacKinnon R (2003). Gating the selectivity filter in ClC chloride channels. Science 300:108 112.
12. + secretion. Nature 414:558 561.
13. Estévez R, Schroeder BC, Accardi A, Jentsch TJ, Pusch M (2003). Conservation of chloride channel structure revealed by an inhibitor binding site in ClC-1. Neuron 38:47 59.
14. + channel subtype-dependent activation by niflumic acid. Mol Pharmacol 73:1159 1167.
15. Fong P (2004). CLC-K channels: if the drug fits, use it. EMBO Rep 5:565 566.
16. Foster RR, Zadeh MA, Welsh GI, Satchell SC, Ye Y, Mathieson PW et al. (2009). Flufenamic acid is a tool for investigating TRPC6-mediated calcium signalling in human conditionally immortalised podocytes and HEK293 cells. Cell Calcium 45:384 390.
17. + channels. Trends Pharmacol Sci 28:1 5.
18. Jeck N, Waldegger S, Lampert A, Boehmer C, Waldegger P, Lang PA et al. (2004). Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension 43:1175 1181.
19. Jentsch TJ (2005). Chloride transport in the kidney: lessons from human disease and knockout mice. J Am Soc Nephrol 16:1549 1561.
20. Kieferle S, Fong P, Bens M, Vandewalle A, Jentsch TJ (1994). Two highly homologous members of the ClC chloride channel family in both rat and human kidney. Proc Natl Acad Sci U S A 91:6943 6947.
21. Kokubo Y, Iwai N, Tago N, Inamoto N, Okayama A, Yamawaki H et al. (2005). Association analysis between hypertension and CYBA, CLCNKB, and KCNMB1 functional polymorphisms in the Japanese population - the Suita study. Circ J 69:138 142. (Pubitemid 40313030)
22. Liantonio A, Accardi A, Carbonara G, Fracchiolla G, Loiodice F, Tortorella P et al. (2002). Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid. Mol Pharmacol 62:265 271.
23. Liantonio A, Pusch M, Picollo A, Guida P, De Luca A, Pierno S et al. (2004). Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride channels blockers. J Am Soc Nephrol 15:13 20.
24. Liantonio A, Picollo A, Babini E, Carbonara G, Fracchiolla G, Loiodice F et al. (2006). Activation and inhibition of kidney CLC-K chloride channels by fenamates. Mol Pharmacol 69:165 173.
25. Liantonio A, Giannuzzi V, Picollo A, Babini E, Pusch M, Conte Camerino D (2007). Niflumic acid inhibits chloride conductance of rat skeletal muscle by directly inhibiting the CLC-1 channel and by increasing intracellular calcium. Br J Pharmacol 150:235 247.
26. - channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands. Proc Natl Acad Sci U S A 105:1369 1373.
27. Lorenz C, Pusch M, Jentsch TJ (1996). Heteromultimeric CLC chloride channels with novel properties. Proc Natl Acad Sci U S A 93:13362 13366.
28. Malykhina AP, Shoeb F, Akbarali HI (2002). Fenamate-induced enhancement of heterologously expressed HERG currents in Xenopus oocytes. Eur J Pharmacol 452:269 277.
29. Matsumura Y, Uchida S, Kondo Y, Miyazaki H, Ko SB, Hayama A et al. (1999). Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1 chloride channel. Nat Genet 21:95 98.
30. Matulef K, Howery AE, Tan L, Kobertz WR, Du Bois J, Maduke M (2008). Discovery of potent CLC chloride channel inhibitors. ACS Chem Biol 3:419 428.
31. Picollo A, Liantonio A, Didonna MP, Elia L, Camerino DC, Pusch M (2004). Molecular determinants of differential pore blocking of kidney CLC-K chloride channels. EMBO Rep 5:584 589.
32. Picollo A, Liantonio A, Babini E, Camerino DC, Pusch M (2007). Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels. J Membr Biol 216:73 82.
33. Pusch M, Steinmeyer K, Jentsch TJ (1994). Low single channel conductance of the major skeletal muscle chloride channel, ClC-1. Biophys J 66:149 152.
34. Pusch M, Liantonio A, Bertorello L, Accardi A, De Luca A, Pierno S et al. (2000). Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivatives. Mol Pharmacol 58:498 507.
35. Pusch M, Liantonio A, De Luca A, Conte Camerino D (2007). Pharmacology of CLC chloride channels and transporters. In:Pusch M (ed.). Chloride Transport across Biological Membranes, Vol. 38. Elsevier
36. - channels inferred from analysis of voltage-dependent block. J Biol Chem 276:18423 18429.
37. - channels: mechanism underlying deafness in Bartter syndrome IV. Embo J 27:2907 2917.
38. Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M et al. (2004). Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med 350:1314 1319.
39. Scholl U, Hebeisen S, Janssen AG, Müller-Newen G, Alekov A, Fahlke C (2006). Barttin modulates trafficking and function of ClC-K channels. Proc Natl Acad Sci U S A 103:11411 11416.
40. Sigworth FJ (1980). The variance of sodium current fluctuations at the node of Ranvier. J Physiol 307:97 129.
41. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R et al. (1997). Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 17:171 178.
42. Speirs HJ, Wang WY, Benjafield AV, Morris BJ (2005). No association with hypertension of CLCNKB and TNFRSF1B polymorphisms at a hypertension locus on chromosome 1p36. J Hypertens 23:1491 1496.
43. Uchida S, Sasaki S (2005). Function of chloride channels in the kidney. Ann Rev Physiol 67:759 778.
44. Uchida S, Sasaki S, Furukawa T, Hiraoka M, Imai T, Hirata Y et al. (1993). Molecular cloning of a chloride channel that is regulated by dehydration and expressed predominantly in kidney medulla. J Biol Chem 268:3821 3824.
45. Verkman AS, Galietta LJ (2008). Chloride channels as drug targets. Nat Rev Drug Discov 19:19.
46. Waldegger S, Jeck N, Barth P, Peters M, Vitzthum H, Wolf K et al. (2002). Barttin increases surface expression and changes current properties of ClC-K channels. Pflügers Arch 444:411 418.
47. Zifarelli G, Pusch M (2007). CLC chloride channels and transporters: a biophysical and physiological perspective. Rev Physiol Biochem Pharmacol 158:23 76.